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Abstract
Two adjacent regions within the transactivation do-
main of p53 are sufficient to support sequence-specific
transactivation when fused to a heterologous DNA
binding domain. It has been hypothesized that these
two subdomains of p53 may contribute to the expres-
sion of distinct p53-responsive genes. Here we have
used oligonucleotide microarrays to identify transcripts
induced by variants of p53 with point mutations within
subdomains 1, 2, or 1 and 2 (QS1, QS2, and QS1/QS2,
respectively). The expression of 254 transcripts was in-
creased in response to wild-type p53 expression but
most of these transcripts were poorly induced by these
variants of p53. Strikingly, a number of known p53-
regulated transcripts including TNFRSF10B, BAX, BTG2,
and POLH were increased to wild-type levels by p53QS1
and p53QS2 but not p53QS1/QS2, indicating that either sub-
domain 1 or 2 is sufficient for p53-dependent expression
of a small subset of p53-responsive genes. Unexpect-
edly, there was no evidence for p53QS1- or p53QS2-specific
gene expression. Taken together, we found hetero-
geneity in the requirement for transactivation subdo-
mains 1 and 2 of p53 without any subdomain-specific
contribution to p53-induced gene expression.
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Introduction
The p53 tumor suppressor plays a pivotal role in preventing
oncogenic transformation [1]. More than half of all human
cancers is associated with alterations in p53 [1]. Decreased
p53 activity is associated with hereditary cancers [2] and
p53 nullizygous mice are cancer-prone [3]. The p53 protein
is a sequence-specific transcription factor that can regulate
the expression of a plethora of genes [1]. This protein is ac-
tivated and accumulates in cells in response to a variety of
cellular stresses and thus is an important regulator of stress
gene regulation [1].
The p53 protein is a modular protein with several well-
characterized functional domains. The C-terminus of p53 is
required for oligomerization and contains sequence-independent
DNA, DNA damage, and RNA binding activities [4]. This region is
dispensable for p53 to function as a transcriptional activator [5,6].
The central third of p53 contains the sequence-specific DNA
binding domain required for p53 to function as a transcriptional
activator [7]. The majority of tumor-associated p53 mutations fall
within the DNA binding domain [8]. The N-terminus of p53 con-
tains an activation domain (AD) that is also required for sequence-
specific transcriptional activation [9,10].
The N-terminal 73 amino acids of p53 expressed as a fusion
protein with the DNA binding domain of the yeast GAL4 protein
functions as an activator of GAL4-dependent gene expression
[10]. The minimal transactivation domain was subsequently lo-
calized to the N-terminal 42 amino acids of p53 [9] and critical
hydrophobic amino acids (Leu-22 and Trp-23) within this acidic
region were found to be important for transactivation [5,11,12].
The mutation of these residues (L22Q/W23S) decreased the
ability of the N-terminal 42 amino acids of p53 to function as an
AD [5,11,12]. The p53L22Q/W23S variant and the murine equiv-
alent (p53L25Q/W26S) are commonly used as transactivation-
deficient versions of p53 [13–17]. Intriguingly, the L22Q/W23S
variant (hereafter referred to as the QS1 variant) reportedly
retains some p53 activity despite a profound transactivation
defect [13,18–20]. Specifically, the QS1 variant retains the
ability to induce apoptosis in some cellular contexts but is
unable to induce G1 arrest [13,14,19,20]. Intriguingly, the ho-
mozygous QS1 knock-in mice undergo embryonic lethality al-
though p53 is not required for embryonic development [14,21].
The QS1 variant is not equivalent to the complete loss of p53.
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A second functional transactivation subdomain in the N-
terminus of p53 has also been identified through a similar
strategy. Amino acids 43 to 73 of p53 fused to the DNA bind-
ing domain of GAL4 were able to drive Gal4-dependent re-
porter gene expression and two critical hydrophobic amino
acids (Trp-53 and Phe-54) were again critical for this activity
[5,11,20]. Like the QS1 variant of p53, the W53Q/F54S var-
iant (hereafter referred to as the QS2 variant) is defective in
sequence-specific transactivation, when the expression of a
small number of well-characterized p53 target genes was
assessed [16,18–20]. Intriguingly, the QS2 variant of p53
was reported to retain the ability to induce p53-dependent
G1 arrest but not p53-dependent apoptosis [20]. Therefore,
despite the fact that the QS1 and QS2 variants of p53 have
defects in sequence-specific transactivation, they exhibit some
distinct biologic activities. This has led several laboratories to
hypothesize that these domains function independently in reg-
ulating distinct subsets of p53 target genes [14,16,19–21].
Before this study, the relative contribution of these two AD
subdomains to p53-mediated gene expression had not been
assessed. Here we used recombinant adenoviruses ex-
pressing wild-type p53, p53QS1, p53QS2, and p53QS1/QS2 to
drive p53-dependent gene expression in colorectal carcinoma
cell lines in which endogenous p53 expression had been abol-
ished by gene targeting. Gene expression was assessed
using Affymetrix Oligonucleotide microarrays containing over
50,000 features. The expression of 254 transcripts was in-
creased in response to Adp53wt infection and approximately
10% of these transcripts was also induced by the QS1 and
QS2 variants but not the compoundmutant. A small number of
these genes were induced to wild-type levels by the QS var-
iants; however, the fold increase in expression of the tran-
scripts induced by the QS1 and QS2 variants was strongly
correlated. These results indicate that the two subdomains co-
operate to activate transcription of most p53 target genes. Our
work also identified another subgroup of p53 target genes that
appear to use either subdomain interchangeably.
Materials and Methods
Cell Culture and UV Treatment
The HCT116 p53/ cell line was kindly provided by Dr.
Bert Vogelstein (John’s Hopkins University). Cells weremain-
tained in McCoy’s 5A media supplemented with 10% fetal
bovine serum (Wisent, St. Bruno, Quebec, Canada). Adeno-
virus constructs expressing p53wt, p53QS1, p53QS2, and
p53QS1/QS2 were kindly provided by Dr. Ruth Slack (Uni-
versity of Ottawa, Ontario, Canada). The adenovirus Ad-
BHGDE1DE3 (Ad-empty) control was generously provided by
Dr. Frank Graham (McMaster University, Canada). Viruses
were propagated using human embryonic kidney (HEK293)
cells and cesium chloride gradient purification [22]. Virus
titers were determined in HEK293 cells by standard methods
[22] and titers are expressed as plaque-forming units per
milliliter (pfu/ml). Cell lines were routinely tested for myco-
plasma contamination.
RNA Isolation and Quantitative Reverse Transcription–
Polymerase Chain Reaction (RT-PCR)
HCT116 p53/ cells at 70% to 80% confluence were
infected at a multiplicity of infection of 25 with indicated ad-
enovirus in serum-freemedia for 1 hour. Growthmedium con-
taining 10% fetal bovine serum was replaced and cells were
returned to the incubator for the indicated time. Infected
cells were collected and total RNA was isolated using the
RNeasy RNA isolation kit (Qiagen, Valencia, CA) according
to manufacturer’s specifications. Five micrograms of total
RNA was reverse-transcribed using a first-strand cDNA
synthesis kit (MBI Fermentas, Burlington, ON, Canada).
Quantitative RT-PCR was performed using the SYBR Green
Fluorescent DNA stain (Invitrogen, Burlington, ON, Canada),
a LightCycler 2 quantitative PCR machine (Roche Diag-
nostics, Mannheim, Germany), and LightCycler software
version 3 (Roche Diagnostics). The primers used were
ACTB (GGGCATGGGTCAGAAGGAT and GTGGCCATCT-
CTTGCTCGA), APAF1 (CAACGGGAGATGACAATG and
CTGGAGAAAAGCAAAGGTC), BAK1 (GCCATCAGCAGG-
AACAGGAG and ACACCCAGAACCACCAGCAC), BTG2
(CACAGAGCACTACAAACACC and ACAAGACGCAGAT-
GGAGC), CASP6 (GCTTTGTGTGTGTCTTCC and CTCA-
GTTATGTTGGTGTCC), CDKN1A (CCTCAAATCGTCCAG-
CGACCTT and CATTGTGGGAGGAGCTGTGAAA),
TNFRSF6 (CTCATCTTAATGGCCTAATGCA and GCTT-
CAGTTTATAACTATCTTCAC), TNFRSF10B (GGCATCA-
TCATAGGAGTCAC and GTCAAAGGGCACCAAGTC),
TP53I3 (TCTCTATGGTCTGATGGG and TTGCCTATGTT-
CTTGTTG), and MafB (TGCTGAGAGAGAGAACCGAGAG
and CACCACCAAGAACTCTTCCTAC).
Microarrays
Total RNA was collected from HCT116p53/ cells
infected for 16 hours with 25 pfu/cell of Ad-BHGDE1DE3,
Adp53wt, Adp53QS1, Adp53QS2, or Adp53QS1/QS2 using the
RNeasy Mini kit (Qiagen). Human Genome U133plus2.0 ol-
igonucleotide arrays (Affymetrix, Santa Clara, CA) were
used for expression analysis. Experimental procedures were
performed according to the manufacturer specifications at
the Ottawa Genomics Innovation Centre Affymetrix Gene-
Chip Facility (Ottawa, Ontario, Canada). Affymetrix Micro-
array Suite 6.0 (MAS6.0) software was used to analyze the
microarray data. MAS6.0 software uses a nonparametric
Wilcoxon signed rank test to determine whether statistically
meaningful differences in probe cell intensities were detected
between samples (change calls were determined using c1H
and c1L values of 0.0025). Genes were considered to be
induced if and only if they were statistically (P V .0025) in-
creased in all experiments compared to Ad-BHGDE1DE3 in-
fected controls by an average of two-fold.
Western Blot Analysis
Total protein was extracted from cells using 1% sodium
dodecyl sulfate and brief sonication. Protein samples were
run on 4% to 12% Bis–Tris acrylamide gels, transferred to
nitrocellulose membrane (Hybond-C; Amersham, Piscataway,
NJ) and blocked with 5% skimmilk–phosphate-buffered saline
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with 1% Tween 20 (TBS–T). Monoclonal antibodies raised
against p53 were DO-1 (Ab6; Calbiochem, San Diego, CA),
Pab1801 (Ab2; Calbiochem), and Pab421 (Ab1; Calbiochem).
Additional antibodies were raised against p21WAF1 (Ab1;
Calbiochem), PUMA (Ab1; Calbiochem), MDM2 (SMP14;
Santa Cruz Biotechnology, Santa Cruz, CA) and MafB
(P-20; Santa Cruz Biotechnology). Anti–mouse immuno-
globulin (IgG) conjugated with horseradish peroxidase was
used as a secondary antibody (Calbiochem), and protein
bands were detected using the SuperSignal WestPico
Chemiluminescent Substrate kit (Pierce, Rockford, IL) after
being exposed to a film (X-OMAT; Kodak, Rochester, NY).
Immunoprecipitation and Mass Spectrometry
HCT116 p53/ cells were infected with a multiplicity of
infectionof 25 of Adp53wt. Twenty-four hours postinfection
cells were washed twice with PBS and scraped into PBS on
ice. Cells were then treated as per manufacturer’s instruc-
tions for the use of Protein A–agarose beads (Roche Diag-
nostics). Protein lysates were immunoprecipitated with p53
antibody Pab421. Precipitated protein extracts were run on a
4% to 12% Bis–Tris polyacrylamide gel and subsequently
treated with GelCode Blue Stain Reagent according to man-
ufacturer’s specifications (Pierce). Bands of interest were ex-
cised and subjected to trypsin digestion. Matrix-assisted laser
desorption/ionization time of flight tandem mass spectrometry
(MALDI-TOF MS/MS) was performed at the Ontario Geno-
mics Innovation Centre Proteomics Facility at the Ottawa
Health Research Institute (Ottawa, Ontario, Canada). Pep-
tides were identified using Mascot [23].
Results
The QS1 and QS2 Variants of p53 Are Impaired in
p53-Dependent Gene Expression
HCT116 cells in which p53 had been inactivated by gene
targeting (HCT116p53/) [24] were infected with recombi-
nant adenoviruses expressing wild-type, QS1, QS2, or QS1/
QS2 variants of p53. Cell lysates were collected for immu-
noblot analysis at various times following infection using a
panel of anti–p53 antibodies. The use of this panel of anti-
bodies allowed us to distinguish between the variant forms of
p53 in all experiments (Figure 1A). Immunoblot analysis re-
vealed the presence of two immunoreactive bands that
migrated at approximately 47 and 53 kDa (Figure 1B). Wild-
type p53 was immunoprecipitated with Pab421 and separated
by sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis. The bands were gel excised and analyzed byMALDI-TOF
mass spectrometry. The seven peptides identified were lo-
cated within the DNA binding domain of p53 (Figure 1A and
Table W1). These peptides coupled with our panel of anti–
p53 antibodies indicated that both bands represent full-
length p53 (Figure 1A). The two forms likely correspond to
Figure 1. Expression of transactivation subdomain variants of p53. (A) Schematic representation of epitopes recognized by the indicated monoclonal antibodies
(DO-1, Pab1801, and Pab421), peptides (P) identified by mass spectroscopy (see Table W1), and p53 functional domains. SD1 and SD2 denote subdomains 1 and
2 within the acidic AD. PRD, proline-rich domain; DBD, DNA binding domain; TD, tetramerization domain; BD, basic domain. Numbers below indicate the amino
acid position. (B) Immunoblot analysis of p53 expression 16 hours following infection of either HCT116p53/ or HeLa cells with the indicated recombinant ad-
enovirus, using three different anti –p53 monoclonal antibodies. M and C represent mock- and control virus– infected samples whereas WT, QS1, QS2, and QS1/
QS2 denote the wild-type and variant forms of p53. Similar blots were obtained with cell lysates derived from HCT116 and MDAH041 cells (data not shown). (C)
Samples were collected at 8, 16, or 24 hours and subsequently analyzed by immunoblot analysis with the Pab421 monoclonal antibody.
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differentially modified forms. However, the N- and C-termini
of p53, containing the knownmodification sites, were not rep-
resented among the identified peptides and thus the specific
modifications were not ascertained. The increased expres-
sion of these variants relative to wild-type p53 was expected
because the QS variants do not induce mdm2 expression
(Figure 1B), the ubiquitin ligase responsible for the rapid turn-
over of wild-type p53 [25].
To identify transcripts induced in response to Adp53wt,
Adp53QS1, Adp53QS2 and Adp53QS1/QS2 infection, microar-
ray analysis was performed using total RNA collected from
HCT116p53/ cells 16 hours post infection because max-
imal p53 levels were achieved within this time frame (Fig-
ure 1C). The expression of 254 transcripts increased
significantly following infection with the Adp53wt virus com-
pared to control virus infection (Table W2). Of these, only 28,
23, and 1 were induced by Adp53QS1, Adp53QS2, and
Adp53QS1/QS2, respectively (Figure 2A and Table W3). The
mean induction of the Adp53wt-induced transcripts was
significantly higher than the fold increase in expression due
to the expression of any of the QS variants (Figure 2B). In
fact, very few of the Adp53wt-induced genes appeared to be
induced to wild-type levels by either the QS1 or QS2 variants
(Figure 2C). Infection with the Adp53wt virus resulted in a
greater increase in gene expression even when examining
genes determined to be induced in response to either
Adp53QS1 or Adp53QS2 infection (Figure 2, D and E). There-
fore, the majority of WT-, QS1-, and QS2-regulated genes
were poorly induced by the QS variants.
Correlation between Genes Induced By the QS1 and
QS2 Variants
Having determined that most Adp53wt-induced genes
were poorly induced by the variants, we sought to determine
whether distinct subgroups of p53 target genes were prefer-
entially responsive to the QS variants of p53. The fold change
in p53 target gene expression in response to Adp53QS1
infection was plotted with respect to Adp53QS2 infection (Fig-
ure 3B). We observed a very striking linear correlation be-
tween the fold change in expression induced by the QS1 and
QS2 variants of p53 regardless of whether the expression of
Adp53wt-, Adp53QS1-, or Adp53QS2-induced genes were con-
sidered (Figure 3B; R2 values were 0.73, 0.64, and 0.61, re-
spectively). Therefore, the Adp53QS1- and Adp53QS2-induced
genes were induced to a similar extent by both variants (Fig-
ure 3B and Table W3). These results indicate that the disrup-
tion of either subdomain of p53 similarly affected the overall
pattern of p53 transcriptional activation. We interpret these
results to indicate that the contribution of transactivation sub-
domains 1 and 2 to p53-mediated gene expression was het-
erogeneous but not subdomain-specific.
Based on our definition of induced genes (see Materials
and Methods section), the expression of 18 genes increased
in response to both QS variants but 10 and 5 wild-type p53-
induced transcripts appeared to be increased in response to
either QS1 or QS2, respectively (Figure 3A). To determine
whether these apparently p53QS1- and p53QS2-specific
genes were in fact specifically and preferentially upregulated
by one of the variants, the pattern of allele-specific gene ex-
pression was confirmed by quantitative RT-PCR for 11 differ-
ent transcripts at several different times following viral infection.
The majority of p53 target genes were poorly induced by the
QS1 and QS2 variants (Figure 4A). Several p53 target genes
were significantly induced by the QS variants but were
induced more strongly by wild-type p53 (Figure 4B). Lastly,
a few target genes were induced to near wild-type levels
by p53QS1 and p53QS2 (Figure 4C). The quantitative RT-
PCR data correlated well with the microarray analysis and
none of the p53-upregulated transcripts examined displayed
a subdomain-specific pattern of gene expression (Figure 4
and Tables W3 and W4). The expression of several p53-
regulated proteins was assessed by immunoblot in inde-
pendent cell lines and no subdomain-specific differences
in protein expression were detected (Figure 1B). Collec-
tively, we interpret our results to indicate that the apparently
p53QS1- and p53QS2-specific targets were not specifically
induced by a single variant. Therefore, the response of p53-
induced transcripts to the QS variants was heterogeneous
but not subdomain-specific.
The 254 Adp53wt-induced genes were subjected to
gene ontology (GO) analysis (http://www.geneontology.org/).
Several genes were associated with the GO terms apopto-
sis (GO:0006915), cell cycle (GO:0007049), and DNA re-
pair (GO:0006281) (Table 1), consistent with known p53
biology [26]. Of these terms, only apoptosis was statistically
overrepresented (P < .01) based on analysis using the web-
based GOstat software (http://gostat.wehi.edu.au/). Consis-
tent with the preponderance of proapoptotic genes, Adp53wt
infection resulted in a significant increase in the proportion of
apoptotic cells (Figure 5, A and B). Both QS variants were
reduced in their capacity to induce cell death and there
was no significant difference in their ability to induce apop-
tosis in these cells (Figure 5, A and B). Most of the apopto-
sis annotated genes were poorly induced by the QS1 and
QS2 variants of p53 compared to wild-type p53 (Table 1).
Therefore, decreased p53-dependent gene expression cor-
related with decreased p53-dependent apoptosis in these
cells. Similarly, the cell cycle–annotated genes were poorly
induced by all variants (Table 1). Interestingly, two of the three
genes associated with DNA repair (BTG2 and POLH ) were
induced to near wild-type levels by the QS1 and QS2 variants
but not the QS1/QS2 variant (Table 1 and Figure 4C). Due to
the limited number of repair-related genes, the significance
of this specific observation remains unclear. Overall, our re-
sults suggest that there is substantial heterogeneity in the
contribution of subdomains 1 and 2 to p53-mediated gene
expression but there are no subdomain-specific effects.
Discussion
The p53 protein can act as both a positive and negative
regulator of gene expression but p53 is best understood as a
transcriptional activator. The p53 protein is a positive regu-
lator of several hundred genes and this is mediated by the
sequence-specific binding of p53 to consensus elements
found in promoters, enhancer regions, introns, or the 5V
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untranslated regions of these genes [1]. Transcriptional acti-
vation further requires the p53-dependent recruitment of the
histone acetyl transferases CBP/p300, general transcription
factors, and RNA polymerase II to the promoter of target
genes [27–30]. The N-terminal AD is required for the recruit-
ment of these proteins and subsequent p53-dependent gene
activation [11,30]. Amino acids 1 to 42 were found to function
as a minimal transcriptional AD [9,10]. However, it was sub-
sequently shown that this minimal region was part of a larger
AD with each of the two subdomains capable of supporting
Figure 2. Most p53 target genes are poorly induced by the QS variants. (A) Two hundred and fifty-four genes were induced by Adp53wt. Of these, only 28, 23, and
1 were induced by QS1, QS2, and QS1/QS2, respectively. (B) The fold increase in expression of these 254 genes was determined following infection of cells with
adenoviruses expressing wild-type, QS1, QS2, or QS1/QS2 variant of p53. The fold increase in the expression following infection with Adp53QS1, Adp53QS2, or
Adp53QS1/QS2 was less than the fold increase in response to Adp53wt infection (one-way analysis of variance followed by a Tukey’s Multiple Comparisons test, P V
.001). (C–E) The fold increase in expression due to Adp53wt expression was compared to the fold increase in expression due to indicated transactivation
subdomain variant of p53 for Adp53wt-, Adp53QS1-, and Adp53QS2-induced genes (C, D, and E, respectively). The 254, 28, and 23 genes induced by Adp53wt,
Adp53QS1, and Adp53QS2 are listed in Tables W2 and W3.
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Figure 3. Correlation between Adp53QS1- and Adp53QS2-induced genes. (A) A Venn diagram is used to represent the overlap between Adp53QS1- and Adp53QS2-
induced genes, as defined in the Materials and Methods section. (B) The effect of Adp53QS1 and Adp53QS2 infection on the expression of the 254 Adp53wt-, 28
Adp53QS1-, and 23 Adp53QS2-induced genes was determined. The genes induced by Adp53wt, Adp53QS1, and Adp53QS2 are listed in Tables W2 and W3. A very
tight correlation (R2 values are inset) between Adp53QS1- and Adp53QS2-induced gene expression was observed within the subset of target genes.
Figure 4. Representative transcripts induced by wild-type p53. (A–C) Expression of the indicated transcript was determined by real-time RT-PCR using samples
collected at the indicated time following virus infection (8, 16, or 24 hours). Expression of -actin was used to normalize all RT-PCR results. Open, black, grey,
hatched, and crosshatched bars represent control, Adp53wt-, Adp53QS1-, Adp53QS2-, and Adp53QS1/QS2-infected samples. Each value represents the mean fold
increase in expression (± SEM) determined from a minimum of three independent experiments.
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sequence-specific transactivation when expressed as a fu-
sion protein with a heterologous DNA binding domain [5,11].
The relative contribution of subdomains 1 and 2 to p53
activity has been examined at the cell biologic level by two
laboratories. Zhu et al. [20] reported that p53QS1 is unable to
induce G1 arrest but retains the ability to induce apoptosis in
tumor cell lines [18]. In contrast, p53QS2 was reportedly able
to induce cell cycle arrest but was impaired in its ability to in-
duce apoptosis in these same cell lines [20]. Cregan et al.
[16] reported that overexpression of either p53QS1 or p53QS2
in neuronal cells led to similar levels of apoptosis but that
forced expression of the p53QS2 variant in p53 nullizygous
neuronal cells led to significantly more apoptosis than the
p53QS1 variant when these cells were subsequently treated
with camptothecin. Based on these studies, it was hypothe-
sized that the p53 transactivation subdomains contribute to
the regulation of distinct subsets of p53 target genes that af-
fect the biologic activity of these variants. However, the rel-
ative contribution of the two distinct subdomains in the AD to
p53-dependent transcriptional activity had remained untested.
Here we found that infection of these cells with re-
combinant adenoviruses expressing p53QS1, p53QS2, and
p53QS1/QS2 resulted in the induction of far fewer p53 tar-
get genes than Adp53wt infection. Approximately 10% of the
Adp53-induced genes were also increased on Adp53QS1 and
Adp53QS2 infection. The identity and fold increase in ex-
pression of the p53QS1- and p53QS2-upregulated genes were
strongly correlated, indicating that these subdomains do not
contribute to the expression of distinct subsets of genes.
The majority of p53-regulated genes were induced poorly
by p53QS1, p53QS2, and p53QS1/QS2, indicating that both
subactivation domains are required to increase the expres-
sion of most p53 target genes. Conversely, a relatively small
number of p53-target genes including TNFRSF10B, BAX,
BTG2, and POLH were induced to near wild-type levels by
p53QS1 and p53QS2, but were poorly induced by p53QS1/QS2.
Therefore, the p53-dependent induction of this subgroup of
p53 target genes requires a functional transactivation do-
main but subdomain 1 or 2 appears to be sufficient and used
interchangeably for p53 target gene expression within this
group of genes. We did not detect any subdomain-specific
p53 target genes.
Like many other transactivation domains, the N-terminus
of p53 is not highly conserved overall at the level of amino
acid sequence; however, there is a high level of sequence
conservation among rodents and primates within subdomain
1 (34% identity; see Figure W1). The region of highest ho-
mology includes amino acids 13 through 26 (93% identity), a
region of p53 termed box 1 [31]. The N-terminus of p53 is rich
in acidic residues characteristic of acidic ADs and is mostly
unstructured under physiological conditions [32]. Box 1 con-
tains a number of hydrophobic residues and nuclear magnetic
resonance studies indicate that amino acids 18 to 26 within
box 1 form a helix within the context of the larger disordered
transactivation domain [32]. Mutation of Leu-22 and Trp-23
within the helical region in the QS1 variant is predicted to
disrupt this region of limited secondary structure [32]. The high
Table 1. Adp53wt-Induced Genes Involved in Apoptosis, Cell Cycle, and/or
DNA Repair.
GO Term* Locus p53 Variant
WT QS1 QS2 QS1/QS2
Apoptosis (GO:0006915) TP53I3 3.9y 2.0 1.3 0.1
TP53INP1 3.8 1.4 1.5 0.4
APAF1 2.8 1.8 1.8 1.0
TNFRSF6 2.4 1.8 1.7 0.9
CASP6 1.7 0.8 0.7 0.4
TNFRSF10B 1.5 0.9 0.8 0.5
MDM2 1.4 0.3 0.1 0.0
BAX 1.4 1.2 0.9 0.2
AKTIP 1.2 0.3 0.4 0.4
AMID 1.2 0.4 0.2 0.2
BID 1.1 0.4 0.3 0.3
CARD10 1.1 0.5 0.4 0.4
BAK1 1.0 0.5 0.4 0.3
TRAF4 1.0 0.4 0.1 0.2
Cell Cycle (GO:0007049) CDKN1A 2.4 1.1 0.8 0.8
SESN1 2.0 0.9 0.8 0.1
GAS2L1 1.4 0.8 0.6 0.4
MDM2 1.4 0.3 0.1 0.0
RB1 1.3 0.8 0.6 0.8
RHOB 1.2 0.4 0.3 0.5
PARD6G 1.2 0.7 0.6 0.4
SFN 1.2 0.4 0.3 0.3
SESN2 1.1 0.3 0.2 0.0
LATS2 1.1 0.5 0.4 0.4
HRAS 1.0 0.5 0.4 0.2
DNA Repair (GO:0006281) BTG2 2.9 2.4 2.0 0.9
POLH 2.2 1.8 1.9 0.9
DDB2 1.1 0.4 0.3 0.3
*Genes involved in apoptosis, cell cycle and DNA repair were identified using
the Gene Ontology database (http://geneontology.org/). Of these GO terms,
only apoptosis (GO:0006915) and related GO terms were significantly over
represented among the Adp53wt-induced genes based on GOstat analysis
(http://gostat.wehi.edu.au/).
yThe mean fold increase in expression (log2) determined from microarray ex-
periments, as described in the Materials and Methods section.
Figure 5. Effect of QS variants of p53 on cell viability and apoptosis. Apop-
tosis and cell viability were assessed 48 hours following infection with either
control adenovirus or adenoviruses expressing the indicated variants of p53.
Apoptosis was assessed by subdiploid DNA content (A) and viability was
assessed by Trypan blue exclusion (B). Each point represents the mean
(±SEM) determined from three independent experiments. Adp53wt induced
more apoptosis than the variants (one-way analysis of variance followed by
Tukey’s Multiple Comparisons test, P V .01 for apoptosis and P V .05 for
viability). No significant difference in viability or apoptosis was observed when
comparing QS1 and QS2 variants.
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level of conservation between mouse and human p53 has
made it possible to generate knock-in mice expressing the
QS1 variant from the endogenous p53 locus [14], as discussed
later. It is likely that this secondary structure is important for
the activity of subdomain 1.
Subdomain 2, within the transactivation domain of p53, is
well conserved among primate species but is poorly con-
served when the sequence comparison is extended to rodent
versions of p53 (Figure W1). The limited homology between
mouse and human p53 makes the QS2 variant more difficult
to model in mice. Much like subdomain 1, hydrophobic res-
idues within subdomain 2 of human p53 give rise to localized
secondary structure within the mostly unstructured acidic AD
(nascent turns between Met-40 and Met-44 and between
Asp-48 and Trp-53) [32–34]. Regions of limited secondary
structure withinmostly unstructured ADs are common among
transcriptional activators [12,30,34,35]. The second subdo-
main of p53 reportedly binds to many proteins known to in-
teract with subdomain 1, such as mdm2, RPA, TFIID, TFIIH,
and p300 [11,27,30,34,36–44]. The QS2 point mutations are
thought to disrupt the localized secondary structure and
would be expected to disrupt protein–protein interactions im-
portant for transcriptional activation [12,30,32–34].
As indicated above, knock-in mice expressing the QS1
variant from the endogenous p53 locus have been generated
[14]. Homozygous p53QS1 expression results in embryonic le-
thality; however, homozygous p53QS1-targeted mouse em-
bryonic fibroblasts (MEFs) were obtained [14]. Using these
MEFs, the induction of five of the six p53 target genes tested
was reduced in the QS1-expressing MEFs compared to con-
trol cell lines following doxorubicin treatment [14]. The single
gene induced by the QS1 variant of murine p53 was BAX [14]
and we similarly found that the human QS1 variant was able
to upregulate BAX expression. Unexpectedly, we found that
the QS1 and QS2 variants similarly increased the expres-
sion of BAX along with three other known p53 target genes
(TNFRSF10B, BTG2, and POLH). Therefore, only one of the
two subdomains appears to be necessary and sufficient for
p53-dependent gene expression of this subset of p53 target
genes. We interpret the heterogenous requirement for sub-
domains 1 and 2 to indicate that the requirement for specific
protein–p53 AD interactions must vary in a p53 target gene–
specific manner.
In summary, our results suggest that compound muta-
tions of critical hydrophobic amino acids in either subdomain
1 or 2 decrease the affinity of the AD for cofactors or other
components of basal transcription apparatus that are rate-
limiting for p53-dependent gene expression, at most p53-
induced promoters. Surprisingly, the induction of a small
subset of p53-responsive genes, including BAX, TNFRSF10B,
BTG2, and POLH, is not limited by mutations in either of the
subdomains alone. Therefore, this latter group of genes ap-
pears to have a less stringent requirement for as yet uniden-
tified protein–protein interactions. Importantly, we did not find
any genes that were preferentially induced by any single AD
variant. Our results support a model in which the transcrip-
tion activation subdomains of p53 contribute equally to p53-
dependent target gene expression.
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